Abstract
IntroductionThe two 52-week Phase III INPULSIS® trials assessed the efficacy and safety of nintedanib in patients with IPF. In both trials, nintedanib significantly reduced the annual rate of decline in...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
